Can nortriptyline be used in a patient with coronary artery disease?

Nortriptyline Should Generally Be Avoided in Patients with Coronary Artery Disease

Nortriptyline can be used in CAD patients only under close supervision and with extreme caution, but it is not a preferred agent and should generally be avoided due to significant cardiovascular risks including tachycardia, conduction delays, arrhythmias, myocardial infarction, and stroke. 1

Critical FDA Warnings for CAD Patients

The FDA drug label explicitly states that "Patients with cardiovascular disease should be given nortriptyline hydrochloride only under close supervision because of the tendency of the drug to produce sinus tachycardia and to prolong the conduction time. Myocardial infarction, arrhythmia, and strokes have occurred." 1

More importantly, nortriptyline is absolutely contraindicated during the acute recovery period after myocardial infarction. 1 This is a hard stop—not a relative contraindication.

Evidence from Clinical Trials

Direct Comparison Studies

In a landmark randomized trial comparing paroxetine versus nortriptyline in 81 depressed patients with ischemic heart disease 2:

• Adverse cardiac events occurred in 18% (7/40) of nortriptyline-treated patients versus only 2% (1/41) of paroxetine-treated patients (p<0.03)
• Nortriptyline caused a sustained 11% increase in heart rate (from 75 to 83 bpm, p<0.001)
• Nortriptyline significantly reduced heart rate variability, a marker of poor cardiac prognosis
• Both drugs were equally effective for depression (55-61% response rates)

Autonomic Function Impact

Nortriptyline demonstrates stronger vagolytic effects compared to SSRIs 3:

• Decreases in total power, ultra-low frequency, very low frequency, and low-frequency heart rate variability measures
• Reduction in high-frequency power during awake periods
• These autonomic changes are associated with increased cardiac risk

Long-term Mortality Data

A 7.2-year observational study of 956 CAD patients found alarming mortality differences 4:

• 52.3% of TCA users died compared to 38.2% in SSRI users and 37.3% in non-users
• Adjusted hazard ratio for TCA use: 1.74 (95% CI 1.12-2.69, p=0.01)
• This association was mediated by differences in autonomic function
• TCA users exhibited lower heart rate variability and higher norepinephrine levels at baseline

Guideline Recommendations

Current cardiovascular guidelines do not recommend tricyclic antidepressants for CAD patients. The 2019 and 2024 ESC guidelines for chronic coronary syndromes 5, 6, 5 and the 2023 AHA/ACC chronic coronary disease guidelines 7 focus on:

• Beta-blockers, ACE inhibitors, and statins as core therapies
• SSRIs (particularly escitalopram) when antidepressants are needed 7
• Behavioral interventions and cardiac rehabilitation for depression management

Safer Alternatives for Depression in CAD

If antidepressant treatment is necessary in a CAD patient:

1. First-line: SSRIs (particularly escitalopram or sertraline)

   • No significant cardiac conduction effects
   • No sustained heart rate increases
   • Lower adverse cardiac event rates 2
   • Escitalopram showed reduced MACE after 8.1 years in ACS patients 7

2. Second-line: SNRIs (duloxetine)

   • Recommended in stroke guidelines as second-line 8
   • Better cardiac safety profile than TCAs

3. Avoid entirely:

   • All tricyclic antidepressants in acute MI recovery 1
   • Nortriptyline in patients with recent MI, arrhythmias, or conduction abnormalities

Clinical Decision Algorithm

If depression treatment is needed in a CAD patient:

• Recent MI (within 1 year): Nortriptyline is contraindicated 1
• Stable CAD with normal EF and no arrhythmias: Use SSRI; nortriptyline only if multiple SSRI/SNRI failures and with cardiology consultation
• CAD with reduced EF, arrhythmias, or conduction disease: Nortriptyline is contraindicated in practice
• Any CAD patient on nortriptyline: Requires close cardiac monitoring including ECG, heart rate, blood pressure, and consideration of switching to SSRI

Common Pitfalls to Avoid

• Do not assume that therapeutic drug monitoring makes nortriptyline safe—even therapeutic levels cause cardiac effects 9
• Do not use nortriptyline as first-line for neuropathic pain in CAD patients—consider gabapentinoids or duloxetine instead
• Do not continue nortriptyline started before CAD diagnosis without reassessing risk-benefit and considering alternatives

Bottom line: While nortriptyline can technically be used in stable CAD under close supervision per FDA labeling, the substantial evidence of increased cardiac events, mortality, and adverse autonomic effects makes SSRIs the clearly superior choice for treating depression in this population. 2, 4, 10